Elucidating mechanisms of drug-induced toxicity

Nature Reviews Drug Discovery

Volumn 4, Issue 5, 2005, Pages 410-420

  Liebler, Daniel C ^a   Guengerich, F Peter ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CELL PROTEIN; CERIVASTATIN; CYTOCHROME P450 3A4; GLUTATHIONE TRANSFERASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METACETAMOL; PARACETAMOL; PENICILLIN G; ROFECOXIB; STRESS ACTIVATED PROTEIN KINASE; TERFENADINE; THIOREDOXIN; TRANILAST; TRANSCRIPTION FACTOR NRF2; TROGLITAZONE; VALPROIC ACID; WARFARIN;

BIOTECHNOLOGY; CHEMICAL REACTION; DISEASE EXACERBATION; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUSTRY; DRUG MARKETING; DRUG METABOLISM; DRUG OVERDOSE; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG TOXICITY; ENZYME INHIBITION; EPILEPSY; GENOTOXICITY; HEART ARRHYTHMIA; HIGH THROUGHPUT SCREENING; HUMAN; HYPERBILIRUBINEMIA; KIDNEY FAILURE; LIVER TOXICITY; MYOSITIS; NEPHROTOXICITY; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN MODIFICATION; PROTEINURIA; REVIEW; RHABDOMYOLYSIS; SIGNAL TRANSDUCTION; SUICIDE ATTEMPT; VALIDATION PROCESS;

ANIMALS; DRUG TOXICITY; HUMANS; PHARMACEUTICAL PREPARATIONS; XENOBIOTICS;

EID: 18944401259     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1720     Document Type: Review

References (121)

1. Borzelleca, J. F. in Principles and Methods of Toxicology 4th Ed. (ed. Hayes, A. W.) 1-21 (Taylor & Francis, Philadelphia, 2001).
2. Borzelleca, J. F. Profiles in toxicology - Paracelsus: herald of modern toxicology. Toxicol. Sci. 53, 2-4 (2000).
3. Rehn, L. Über Blasentumoren bei Fuchsinarbeitern. Archiv Clin. Chirgurie 50, 588-600 (1895).
4. Lacassagne, A. Apparition de cancers de la mamelle chez la souris male, soumise a des injections de folliculine. C. R. Acad. Sci. 195, 630-632 (1932).
5. Hueper, W. C. Occupational Tumors and Allied Diseases (Thomas, Springfield, 1942).
6. Speirs, A. L. Thalidomide and congenital abnormalities. Lancet 1, 303-305 (1962).
7. Evans, D. C., Watt, A. P., Nicoll-Griffith, D. A. & Baillie, T. A. Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem. Res. Toxicol. 17, 3-16 (2004).
8. Fura, A. et al. Discovering drugs through biological transformation: role of pharmacologically active metabolites in drug discovery. J. Med. Chem. 47, 4339-4351 (2004).
9. Sussman, N. M. & McLain, L. W. Jr. A direct hepatotoxic effect of valproic acid. J. Am. Med. Assoc. 242, 1173-1174 (1979).
10. Moult, P. J. & Sherlock, S. Halothane-related hepatitis. A clinical study of twenty-six cases. Q. J. Med. 44, 99-114 (1975).
11. Miller, J. A. Carcinogenesis by chemicals: an overview. G. H. A. Clowes Memorial Lecture. Cancer Res. 30, 559-576 (1970).
12. Miller, J. A. Brief history of chemical carcinogenesis. Cancer Lett. 83, 9-14 (1994).
13. Mitchell, J. R. et al. Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism. J. Pharmacol. Exp. Ther. 187, 185-194 (1973).
14. Jollow, D. J. et al. Acetaminophen-induced hepatic necrosis. II. Role of covalent binding in vivo. J. Pharmacol. Exp. Ther. 187, 195-202 (1973).
15. Yamazaki, H. et al. Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P450 2C8 and 3A4 in human liver microsomes. Drug Metab. Dispos. 27, 1260-1266 (1999).
16. Kassahun, K. et al. Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission. Chem. Res. Toxicol. 14, 62-70 (2001).
17. Streeter, A. J., Bjorge, S. M., Axworthy, D. B., Nelson, S. D. & Baillie, T. A. The microsomal metabolism and site of covalent binding to protein of 3′-hydroxyacetanilide, a nonhepatotoxic positional isomer of acetaminophen. Drug Metab. Dispos. 12, 565-576 (1984).
18. Roberts, S. A., Price, V. F. & Jollow, D. J. Acetaminophen structure-toxicity studies: in vivo covalent binding of a nonhepatotoxic analog, 3-hydroxyacetanilide. Toxicol. Appl. Pharmacol. 105, 195-208 (1990).
19. Evans, D. C. & Baillie, T. A. Minimizing the potential for metabolic activation as an integral part of drug design. Curr. Opin. Drug Discov. Devel. 8, 44-50 (2005).
20. 2+ in cell killing. Chem. Res. Toxicol. 3, 484-494 (1990).
21. Trump, B. F. & Berezesky, I. K. Calcium-mediated cell injury and cell death. FASEB J. 9, 219-228 (1995).
22. McConkey, D. J. & Orrenius, S. The role of calcium in the regulation of apoptosis. Biochem. Biophys. Res. Commun. 239, 357-366 (1997).
23. Gibson, J. D., Pumford, N. R., Samokyszyn, V. M. & Hinson, J. A. Mechanism of acetaminophen-induced hepatotoxicity: covalent binding versus oxidative stress. Chem. Res. Toxicol. 9, 580-585 (1996).
24. Smith, C. V., Jones, D. P., Guenthner, T. M., Lash, L. H. & Lauterburg, B. H. Compartmentation of glutathione: implications for the study of toxicity and disease. FEBS Lett. 391, 126-130 (1996).
25. Wyllie, A. H., Morris, R. G., Smith, A. L. & Dunlop, D. Chromatin cleavage in apoptosis: association with condensed chromatin morphology and dependence on macromolecular synthesis. J. Pathol. 142, 67-77 (1984).
26. McConkey, D. J. & Orrenius, S. Signal transduction pathways to apoptosis. Trends Cell. Biol. 4, 370-375 (1994).
27. Beaune, P., Pessayre, D., Dansette, P., Mansuy, D. & Manns, M. Autoantibodies against cytochromes P450: role in human diseases. Adv. Pharmacol. 30, 199-245 (1994).
28. Schaefer, W. H. et al. Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats. Toxicol. Appl. Pharmacol. 194, 10-23 (2004).
29. Johnson, T. E. et al. Statins induce apoptosis in rat and human myotube cultures by inhibiting protein geranylgeranylation but not ubiquinone. Toxicol. Appl. Pharmacol. 200, 237-250 (2004).
30. Shitara Y., Hirano, M., Sato, H. & Sugiyama, Y. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J. Pharmacol. Exp. Ther. 311, 228-236 (2004).
31. Reddy, L. R. & Corey, E. J. Facile air oxidation of the conjugate base of rofecoxib (Vioxx), a possible contributor to chronic human toxicity. Tetrahedron Lett. 46, 927-929 (2005).
32. Egan, K. M. et al. COX-2-derived prostacyclin confers atheroprotection on female mice. Science 306, 1954-1957 (2004.
33. Egan, K. M. et al. Cyclooxygenases, thromboxane, and artherosclerosis. Plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation 111, 334-342 (2005).
34. Gill, H. J. et al. The relationship between the disposition and immunogenicity of sulfamethoxazole in the rat. J. Pharmacol. Exp. Ther. 282, 795-801 (1997).
35. Demoly, P. & Hillaire-Buys, D. Classification and epidemiology of hypersensitivity drug reactions. Immunol. Allergy Clin. North Am. 24, 345-356 (2004).
36. Pichler, W. J. Delayed drug hypersensitivity reactions. Ann. Intern. Med. 139, 683-693 (2003).
37. deShazo, R. D. & Kemp, S. F. Allergic reactions to drugs and biologic agents. J. Am. Med. Assoc. 278, 1895-1906 (1997).
38. Honig, P. K., Woosley, R. L., Zamani, K., Conner, D. P. & Cantilena, L. R. Jr. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin. Pharmacol. Ther. 52, 231-238 (1992).
39. Waring, J. F. & Anderson, M. G. Idiosyncratic toxicity: mechanistic insights gained from analysis of prior compounds. Curr. Opin. Drug Discov. Devel. 8, 59-65 (2005).
40. Shenton, J. M., Chen, J. & Uetrecht, J. P. Animal models of idiosyncratic drug reactions. Chem. Biol. Interact. 150, 53-70 (2004).
41. Rosen, H. et al. Reduced immunotoxicity and preservation of antibacterial activity in a releasable side-chain carbapenum antibiotic. Science 283, 703-706 (1999).
42. Mitchell, J. R. Acetaminophen toxicity. N. Engl. J. Med. 319, 1601-1602 (1988).
43. Yun, C.-H., Okerholm, R. A. & Guengerich, F. P. Oxidation of the antihistaminic drug terfenadine in human liver microsomes: role of cytochrome P450 3A(4) in N-dealkylation and C-hydroxylation. Drug Metab. Dispos. 21, 403-409 (1993).
44. von Moltke, L. L., Greenblatt, D. J., Duan, S. X., Harmatz, J. S. & Shader, R. I. In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction. J. Clin. Pharmacol. 34, 1222-1227 (1994).
45. Guengerich, F. P. & Shimada, T. Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem. Res. Toxicol. 4, 391-407 (1991).
46. McCann, J., Choi, E., Yamasaki, E. & Ames, B. N. Detection of carcinogens as mutagens in the Salmonella/microsome test: assay of 300 chemicals. Proc. Natl Acad. Sci. USA 72, 5135-5139 (1975).
47. Brusick, D. in Principles and Methods of Toxicology 3rd edn (ad. Hayes, A. W.) 545-577 (Raven, New York, 1994).
48. Oda, Y., Nakamura, S., Oki, I., Kato, T. & Shinagawa, H. Evaluation of the new system (umu-test) for the detection of environmental mutagens and carcinogens. Mutat. Res. 147, 210-229 (1985).
49. Weinshilboum, R. & Wang, L. Pharmacogenomics: bench to bedside. Nature Rev. Drug Discov. 3, 739-748 (2004).
50. Nebert, D. W. The Ah locus: genetic differences in toxicity, cancer, mutation, and birth defects. CRC Crit. Rev. Toxicol. 20, 153-174 (1989).
51. Nebert, D. W., Dalton, T. P., Okey, A. B. & Gonzalez, F. J. Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer. J. Biol. Chem. 279, 23847-23850 (2004).
52. Danoff, T. M. et al. A Gilbert's syndrome UGT1A1 variant confers susceptibility to tranilast-induced hyperbilirubinemia. Pharmacogenomics J. 4, 49-53 (2004).
53. Steward, D. J. et al. Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics 7, 361-367 (1997).
54. Waters, M. D. & Fostel, J. M. Toxicogenomics and systems toxicology: aims and prospects. Nature Rev. Genet. 5, 936-948 (2004).
55. Fielden, M. R. & Zacharewski, T. R. Challenges and limitations of gene expression profiling in mechanistic and predictive toxicology. Toxicol. Sci. 60, 6-10 (2001).
56. Hamadeh, H. K. et al. Integration of clinical and gene expression endpoints to explore furan-mediated hepatotoxicity. Mutat Res. 549, 169-183 (2004).
57. Amin, R. P. et al. Identification of putative gene based markers of renal toxicity. Environ. Health Perspect. 112, 465-479 (2004).
58. Thomas, R. S. et al. Identification of toxicologically predictive gene sets using cDNA microarrays. Mol. Pharmacol. 60, 1189-1194 (2001).
59. Baker, T. K. et al. Temporal gene expression analysis of monolayer cultured rat hepatocytes. Chem. Res. Toxicol. 14, 1218-1231 (2001).
60. Burczynski, M. E. et al. Toxicogenomics-based discrimination of toxic mechanism in HepG2 human hepatoma cells. Toxicol. Sci. 58, 399-415 (2000).
61. McMillian, M. et al. A gene expression signature for oxidant stress/reactive metabolites in rat liver. Biochem. Pharmacol. 68, 2249-2261 (2004).
62. Waring, J. F. et al. Identifying toxic mechanisms using DNA microarrays: evidence that an experimental inhibitor of cell adhesion molecule expression signals through the aryl hydrocarbon nuclear receptor. Toxicology 181-182, 537-550 (2002).
63. Waring, J. F., Ciurlionis, R., Jolly, R. A., Heindel, M. & Ulrich, R. G. Microarray analysis of hepatotoxins in vitro reveals a correlation between gene expression profiles and mechanisms of toxicity. Toxicol. Lett. 120, 359-368 (2001).
64. Waring, J. F. et al. Clustering of hepatotoxins based on mechanism of toxicity using gene expression profiles. Toxicol. Appl. Pharmacol. 175, 28-42 (2001).
65. Suter, L., Babiss, L. E. & Wheeldon, E. B. Toxicogenomics in predictive toxicology in drug development. Chem. Biol. 11, 161-171 (2004).
66. Searfoss, G. H. et al. Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional gamma-secretase inhibitor. J. Biol. Chem. 278, 46107-46116 (2003).
67. Milano, J. et al. Modulation of notch processing by gamma-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol. Sci. 82, 341-358 (2004).
68. Jelinsky, S. A. & Samson, L. D. Global response of Saccharomyces cerevisiae to an alkylating agent. Proc. Natl Acad. Sci. USA 96, 1486-1491 (1999).
69. Jelinsky S. A., Estep, P., Church, G. M. & Samson, L. D. Regulatory networks revealed by transcriptional profiling of damaged Saccharomyces cerevisiae cells: Rpn4 links base excision repair with proteasomes. Mol. Cell. Biol. 20, 8157-8167 (2000).
70. Haugen, A. C. et al. Integrating phenotypic and expression profiles to map arsenic-response networks. Genome Biol. 5, R95 (2004).
71. Begley, T. J., Rosenbach, A. S., Ideker, T. & Samson, L. D. Damage recovery pathways in Saccharomyces cerevisiae revealed by genomic phenotyping and interactome mapping. Mol. Cancer Res. 1, 103-112 (2002).
72. Said, M. R., Begley, T. J., Oppenheim, A. V., Lauffenburger, D. A. & Samson, L. D. Global network analysis of phenotypic effects: protein networks and toxicity modulation in Saccharomyces cerevisise. Proc. Natl Acad. Sci. USA 101, 18006-18011 (2004).
73. Begley, T. J., Rosenbach, A. S., Ideker, T. & Samson, L. D. Hot spots for modulating toxicity identified by genomic phenotyping and localization mapping. Mol. Cell 16, 117-125 (2004).
74. Xenarios, I. et al. DIP, the Database of Interacting Proteins: a research tool for studying cellular networks of protein interactions. Nucleic Acids Res. 30, 303-305 (2002).
75. Giaever, G. et al. Functional profiling of the Saccharomyces cerevisiae genome. Nature 418 387-391 (2002).
76. Pothof, J. et al. Identification of genes that protect the C. elegans genome against mutations by genome-wide RNAi. Genes Dev. 17, 443-448 (2003).
77. Aebersold, R. & Mann, M. Mass spectrometry-based proteomics. Nature 422, 198-207 (2003).
78. Liebler, D. C. Introduction to Proteomics. Tools for the New Biology (Humana, Totowa, 2002).
79. Bandara, L. R., Kelly, M. D., Lock, E. A. & Kennedy, S. A correlation between a proteomic evaluation and conventional measurements in the assessment of renal proximal tubular toxicity. Toxicol. Sci. 73, 195-206 (2003).
80. Ruepp, S. U., Tonge, R. P., Shaw, J., Wallis, N. & Pognan, F. Genomics and proteomics analysis of acetaminophen toxicity in mouse liver. Toxicol. Sci. 65, 135-150 (2002).
81. Ishimura, R. et al. Altered protein profile and possible hypoxia in the placenta of 2,3,7,8-tetrachlorodibenzo-p-dioxin-exposed rats. Toxicol. Appl. Pharmacol. 185, 197-206 (2002).
82. Wulfkuhle, J. D., Liotta, L. A. & Petricoin, E. F. Proteomic applications for the early detection of cancer. Nature Rev. Cancer 3, 267-275 (2003).
83. Gao, J. et al. Identification of in vitro protein biomarkers of idiosyncratic liver toxicity. Toxicol. In Vitro 18, 533-541 (2004).
84. Jones, J. A., Kaphalia, L., Treinen-Moslen, M. & Liebler, D. C. Proteomic characterization of metabolites, protein adducts, and biliary proteins in rats exposed to 1,1-dichloroethylene or diclofenac. Chem. Res. Toxicol. 16, 1306-1317 (2003).
85. Qiu, Y., Benet, L. Z. & Burlingame, A. L. Identification of the hepatic protein targets of reactive metabolites of acetaminophenin in vivo in mice using two-dimensional gel electrophoresis and mass spectrometry. J. Biol. Chem. 273, 17940-17953 (1998).
86. Lame, M. W., Jones, A. D., Wilson, D. W., Dunston, S. K. & Segall, H. J. Protein targets of monocrotaline pyrrole in pulmonary artery endothelial cells. J. Biol. Chem. 275, 29091-29099 (2000).
87. MacCoss, M. J. et al. Shotgun identification of protein modifications from protein complexes and lens tissue. Proc. Natl Acad. Sci. USA 99, 7900-7905 (2002).
88. Liebler, D. C. Proteomic approaches to characterize protein modifications; new tools to study the effects of environmental exposures. Environ. Health Perspect. 110 Suppl 1, 3-9 (2002).
89. Hansen, B. T., Jones, J. A., Mason, D. E. & Liebler, D. C. SALSA: a pattern recognition algorithm to detect electrophile-adducted peptides by automated evaluation of CID spectra in LC-MS-MS analyses. Anal. Chem. 73, 1676-1683 (2001).
90. Hansen, B. T., Davey, S. W., Ham, A. J. L. & Liebler, D. C. P-Mod: an algorithm and software to map modifications to peptide sequences from tandem MS data. J. Proteome Res. (in the press).
91. Lindon, J. C. et al. Contemporary issues in toxicology the role of metabonomics in toxicology and its evaluation by the COMET project. Toxicol. Appl. Pharmacol. 187, 137-146 (2003).
92. Plumb, R. S. et al. Use of liquid chromatography/time-of-flight mass spectrometry and multivariate statistical analysis shows promise for the detection of drug metabolites in biological fluids. Rapid Commun. Mass Spectrom. 17, 2632-2638 (2003).
93. Plumb, R. S. et al. Metabonomics: the use of electrospray mass spectrometry coupled to reversed-phase liquid chromatography shows potential for the screening of rat urine in drug development. Rapid Commun. Mass Spectrom. 16, 1991-1996 (2002).
94. Bollard, M. E., Stanley, E. G., Lindon, J. C., Nicholson, J. K. & Holmes, E. NMR-based metabonomic approaches for evaluating physiological influences on biofluid composition. NMR Biomed. (in the press).
95. Nguyen, T., Sherratt, P. J. & Pickett, C. B. Regulatory mechanisms controlling gene expression mediated by the antioxidant response element. Annu. Rev. Pharmacol. Toxicol. 43, 233-260 (2003).
96. Wakabayashi, N. et al. Protection against electrophile and oxidant stress by induction of the phase 2 response: fate of cysteines of the Keap1 sensor modified by inducers. Proc. Natl Acad. Sci. USA 101, 2040-2045 (2004).
97. Itoh, K. et al. Keap1 represses nuclear activation of anti-oxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev. 13, 76-86 (1999).
98. McMahon, M., Itoh, K., Yamamoto, M. & Hayes, J. D. Keap1-dependent proteasomal degradation of transcription factor Nrf2 contributes to the negative regulation of antioxidant response element-driven gene expression. J. Biol. Chem. 278, 21592-21600 (2003).
99. Kang, M. I., Kobayashi, A., Wakabayashi, N., Kim, S. G. & Yamamoto, M. Scaffolding of Keap1 to the actin cytoskeleton controls the function of Nrf2 as key regulator of cytoprotective phase 2 genes. Proc. Natl Acad. Sci. USA 101, 2046-2051 (2004).
100. Zhang, D. D. & Hannink, M. Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress. Mol. Cell Biol. 23, 8137-8151 (2003).
101. Dinkova-Kostova, A. T. et al. Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc. Natl Acad. Sci. USA 99, 11908-11913 (2002).
102. Kwak, M. K. et al. Modulation of gene expression by cancer chemopreventive dithiolethiones through the Keap1-Nrf2 pathway: identification of novel gene clusters for cell survival. J. Biol. Chem. 278, 8135-8145 (2003).
103. 1 binding to DNA in vivo in rats fed phenolic antioxidants, ethoxyquin and a dithiolthione. [i Carcinogenesis 6, 759-763 (1985).
104. Talalay, P., Fahey, J. W., Holtzclaw, W. D., Prestera, T. & Zhang, Y. Chemoprotection against cancer by Phase 2 enzyme induction. Toxicol. Lett. 82-83, 173-179 (1995).
105. Dinkova-Kostova, A. T., Massiah, M. A., Bozak, R. E., Hicks, R. J. & Talalay, P. Potency of Michael reaction acceptors as inducers of enzymes that protect against carcinogenesis depends on their reactivity with sulfhydryl groups. Proc. Natl Acad. Sci. USA 98, 3404-3409 (2001).
106. Holtzclaw, W. D., Dinkova-Kostova, A. T. & Talalay, P. Protection against electrophile and oxidative stress by induction of Phase 2 genes: the quest for the elusive sensor that responds to inducers. Adv. Enzyme Regul. 44, 335-367 (2004).
107. Armstrong, R. N. Structure, catalytic mechanism, and evolution of the glutathione transferases. Chem. Res. Toxicol. 10, 2-18 (1997).
108. Dorion, S., Lambert, H. & Landry, J. Activation of the p38 signaling pathway by heat shock involves the dissociation of glutathione S-transferase Mu from Ask1. J. Biol. Chem. 277, 30792-30797 (2002).
109. Ichijo, H. et al. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science 275, 90-94 (1997).
110. Karin, M., Yamamoto, Y. & Wang, Q. M. The IKK NF-κB system: a treasure trove for drug development. Nature Rev. Drug Discov. 3, 17-26 (2004).
111. Rossi, A. et al. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase. Nature 403, 103-108 (2000).
112. Ji, C., Kozak, K. R. & Marnett, L. J. IκB kinase, a molecular target for inhibition by 4-hydroxy-2-nonenal. J. Biol. Chem. 276, 18223-18228 (2001).
113. 2 inhibits multiple steps in the NF-KB signaling pathway. Proc. Natl Acad. Sci. USA 97, 4844-4849 (2000).
114. Rhee, S. G., Bae, Y. S., Lee, S. R. & Kwon, J. Hydrogen peroxide: a key messenger that modulates protein phosphorylation through cysteine oxidation. Science STKE 53, E1 (2000).
115. 2+ disturbances, and cell death in renal epithelial cells. J. Biol. Chem. 272, 21751-21759 (1997).
116. Halleck, M. M., Holbrook, N. J., Skinner, J., Liu, H. & Stevens, J. L. The molecular response to reductive stress in LLC-PK1 renal epithelial cells: coordinate transcriptional regulation of gadd153 and grp78 genes by thiols. Cell Stress. Chaperones 2, 31-40 (1997).
117. van de Water, B. et al. Distinct endoplasmic reticulum signaling pathways regulate apoptotic and necrotic cell death following iodoacetamide treatment. Chem. Res. Toxicol. 12, 943-951 (1999).
118. Martinou, J. C. & Green, D. R. Breaking the mitochondrial barrier. Nature Rev. Mol. Cell Biol. 2, 63-67 (2001).
119. Green, D. R. & Kroemer, G. The pathophysiology of mitochondrial cell death. Science 305, 626-629 (2004).
120. Johnson, D. E., Smith, D. A. & Park, B. K. Linking toxicity and chemistry: think globally, but act locally? Curr. Opin. Drug Discov. Devel. 7, 33-35 (2004).
121. Guengerich, F. P. Where is toxicology headed in the future? Drug Metab. Rev. 36, 473-484 (2004).